Damon Runyon Researchers

Meet Our Scientists
Charles S. Dai, MD

Some breast cancers and most prostate cancers express high levels of androgen receptors. Curiously, both activation and inhibition of androgen receptor signaling can result in tumor shrinkage, and the molecular mechanisms driving these opposing effects remain unclear. By studying circulating tumor cells from the blood, Dr. Dai and his colleagues found that this paradoxical effect is mainly caused by abnormal binding of androgen receptors to DNA, changing its three-dimensional structure and resulting in the shutdown of a key cancer gene called MYC. Dr. Dai may have discovered a way to therapeutically target MYC, which has long been a challenging drug target, by overactivating androgen receptors to disrupt the DNA structure required to keep MYC turned on. This could be a promising new strategy to treat certain breast and prostate cancers. He is now investigating why this effect occurs, and how many cancers could be treated this way. Dr. Dai’s research could lead to a new approach to cancer treatment: activating androgen receptors to disrupt the genes that cancers rely on to grow.

Project title: Epigenetically targeting MYC through paradoxical nuclear receptor activation in hormone-dependent malignancies
Institution: Massachusetts General Hospital
Award Program: Physician-Scientist
Sponsor(s) / Mentor(s): Daniel A. Haber, MD, PhD, and Shyamala Maheswaran, PhD
Cancer Type: Breast
Research Area: Chromatin Biology